

Amendments to the Claims

Please cancel Claims 4, 9, 11, 13, 15, 17, 19-21 and 24-33. Please amend Claims 5, 8, 10 and 16. The Claim Listing below will replace all prior versions of the claims in the application:

Claim Listing

1. (Original) A method of inhibiting stenosis or restenosis of a blood vessel following vascular injury in a subject, comprising administering to said subject a therapeutically effective amount of a first therapeutic agent and a therapeutically effective amount of a second therapeutic agent, wherein
said first therapeutic agent inhibits the adhesion and/or recruitment of neutrophils to a site of vascular injury; and
said second therapeutic agent inhibits the adhesion and/or recruitment of mononuclear cells to a site of vascular injury.
2. (Original) The method of Claim 1, wherein said vascular injury arises from a vascular intervention procedure.
3. (Original) The method of Claim 2, wherein said procedure is selected from the group consisting of angioplasty, vascular by-pass surgery, vascular grafting, endarterectomy, atherectomy, endovascular stenting, insertion of prosthetic valve and transplantation of organs, tissues or cells.
4. (Canceled)
5. (Currently amended) The method of Claim [[4]] 1, wherein said first therapeutic agent is an integrin antagonist.
6. (Original) The method of Claim 5, wherein said antagonist inhibits cellular adhesion mediated through a β 2 integrin.

7. (Original) The method of Claim 6, wherein said $\beta 2$ integrin is selected from the group consisting of CD11a/CD18, CD11b/CD18, CD11c/CD18 and CD11d/CD18.
8. (Currently amended) The method of Claim [[4]] 5, wherein said ~~cellular adhesion molecule~~ integrin antagonist is an antibody or antigen-binding fragment thereof.
9. (Canceled)
10. (Currently amended) The method of Claim [[9]] 8, wherein said antibody or antigen-binding fragment binds CD18.
11. (Canceled)
12. (Original) The method of Claim 1, wherein said second therapeutic agent is an antagonist of chemokine receptor function.
13. (Canceled)
14. (Original) The method of Claim 12, wherein said antagonist of chemokine receptor function is an antibody or antigen-binding fragment thereof.
15. (Canceled)
16. (Currently amended) The method of Claim [[15]] 14, wherein said antibody or antigen-binding fragment binds CC-chemokine receptor 2.
17. (Canceled)
18. (Original) A method of inhibiting stenosis or restenosis of a blood vessel following angioplasty in a subject, comprising administering to said subject a therapeutically

effective amount of a first therapeutic agent and a therapeutically effective amount of a second therapeutic agent, wherein

said first therapeutic agent is an antibody or antigen-binding fragment thereof which binds a cellular adhesion molecule and thereby inhibits the adhesion and/or recruitment of neutrophils to a site of vascular injury; and

said second therapeutic agent is an antagonist of CCR2 function.

19-21. (Canceled)

22. (Original) The method of Claim 18, wherein said first therapeutic agent binds CD18.

23. (Original) The method of Claim 18, wherein said second therapeutic agent is an antibody or antigen-binding fragment thereof.

24-33. (Canceled)

34. (Original) A method of inhibiting stenosis or restenosis of a blood vessel following a vascular injury, comprising administering to said subject a therapeutically effective amount of a first therapeutic agent and a therapeutically effective amount of a second therapeutic agent, wherein

said first therapeutic agent is an anti-CD18 antibody or antigen-binding fragment thereof which binds CD18 and inhibits binding of a ligand to an integrin which contains CD18, and

said second therapeutic agent is an anti-CCR2 antibody or antigen-binding fragment thereof which binds CCR2 and inhibits binding of a ligand to said CCR2.

35. (Original) The method of Claim 34, wherein said anti-CD18 antibody or antigen-binding fragment thereof inhibits binding of a ligand selected from the group consisting of ICAM-

- 1, ICAM-2 and fibrinogen to an integrin selected from the group consisting of CD11a/CD18, CD11b/CD18, CD11c/CD18 and CD11d/CD18.
36. (Original) The method of Claim 34, wherein said anti-CCR2 antibody or antigen-binding fragment thereof inhibits binding of a ligand selected from the group consisting of MCP-1, MCP-2, MCP-3, MCP-4 and MCP-5 to said CCR2.
37. (Original) The method of Claim 34, wherein said vascular injury arises from a vascular intervention procedure.
38. (Original) The method of Claim 37, wherein said vascular intervention procedure is selected from the group consisting of angioplasty, vascular by-pass surgery, vascular grafting, endarterectomy, atherectomy, endovascular stenting, insertion of prosthetic valve and transplantation of organs, tissues or cells.
39. (Original) The method of Claim 37, wherein said vascular intervention procedure comprises placement of a stent.